Ashish Anjankar

Ashish Anjankar

Auto-generated profile, based on publicly available information

Ashish Anjankar

Datta Meghe Institute of Medical Sciences

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in International Journal of Current Research and Review
Verified
Journal Article
Closed access
PWPrajakta Warjukar
Prajakta Warjukar
PJPradip Jain
Pradip Jain
PKPrakash Kute
Prakash Kute
AAAshish Anjankar
Ashish Anjankar
SGS.S. Ghangale
S.S. Ghangale

1 January 2024 in Eurasian Journal of Medical Advances
Verified
Journal Article
Closed access
SSSaumya Singh
Saumya Singh
AAAshish Anjankar
Ashish Anjankar
SSSurbhi Singh
Surbhi Singh
RSRoyana Singh
Royana Singh
Objectives: Wilson disease is an autosomal recessive copper balance disorder that causes liver damage and neurological disturbances to varying degrees. ATP7B protein, a hepatic copper-transporting protein, which is encoded by the defective gene ATP7B, is essential to human copper metabolism. A molecular docking technique has been employed to explore the potential of natural compounds targeting ATP7B protein as therapeutic agents for Wilson's disease. Methods: Neuroprotective natural compounds were screened based on the Lipinski Rule of 5, well-established criteria for drug-likeness. Molecular docking was performed using AutoDock 4, and the resulting complex structures were visualized and analyzed with the Biovia Discovery Studio 2020 visualizer. Subsequently, a detailed docking analysis of the selected natural compounds was conducted to identify potential lead compounds with high binding affinities to ATP7B protein. Docking of known drugs were also performed with ATP7B protein to compare the binding energies of the known drugs with top 5 selected natural compounds. Results: Among all the docked compounds, the top five natural compounds, namely Disogenin, Hecogenin, Withanolides, Berberine, and Anaferine. Their binding energies ranged between -9.04 kcal/mol to -7.32 kcal/mol, suggesting strong interactions. Non-bonded interactions of these compounds show favorable interactions with ATP7B protein. All the selected synthetic compounds name as D-Pencillamine, Tetrathimolybdate, and Trientine showed higher binding energies of -3.65 kcal/mol, -5.02 kcal/mol, and -7.20 kcal/mol. Conclusion: As compared to known synthetic drugs our findings revealed that Disogenin, Hecogenin, Berberine, and Anaferine, demonstrated the lowest binding energies with ATP7B protein. As we know that synthetic drugs have also adverse side effects as compare to natural drugs. These compounds can serve as potential therapeutic agents against Wilson's disease, offering a new avenue for the development of treatments targeting the mutated protein for molecular mechanisms of this devastating condition. Further experimental validation is warranted to confirm the efficacy and safety of these compounds in the context of Wilson disease therapy.

7 January 2021 in Indian Journal of Forensic Medicine & Toxicology
Verified
Journal Article
Open access
AAAnjankar Ashish
Anjankar Ashish
NSNinave Sudhir
Ninave Sudhir
GMGaurav V. Mishra
Gaurav V. Mishra
AAAshish Anjankar
Ashish Anjankar

11 July 2022
Verified
Preprint
Open access
PDF file
AAAshish Anjankar
Ashish Anjankar
NCNamrata Choudhary
Namrata Choudhary
ADArchana Dhok
Archana Dhok
RJRoshan Jha
Roshan Jha
This case concerns 8-year-old boy who reported the chief complaints of severe nausea, persistent sore throat and pain in the abdomen. Laboratory investigation reveals high unconjugated serum bilirubin levels with normal liver function enzymes. One month of oral phenobarbital therapy showed an excellent response and lowered hyperbilirubinemia significantly.